2013 SPRING - How Is Pharma R&D Exploiting Big Data?
DATE, LOCATION & HOST
The 2013 spring PRISME Forum Technical Meeting was held Thursday, May 16, 2013, and was hosted by Sanofi at its campus in Chilly-Mazarin, France.
The meeting was preceded by a group reception on Wednesday, May 15, 2013.
PRISME Forum Technical Meeting Chair: Olivier Gien, Sanofi
PRISME Forum Chair: Matteo di Tommaso, Pfizer
SPRING 2013 TECH MEETING
Meeting hosted by Sanofi
How Is Pharma R&D Exploiting Big Data?
Analysis and visualisation of internally generated and externally hosted big data is critical to the on-going success of the Pharma R&D organisation as it searches for patterns, trends and sequences in the drug discovery and clinical trials process. The ‘Big Data’ challenge is rapidly becoming a key strategic theme for the pharmaceutical sector as the industry is faced with an explosion of biomedical data being generated and made available for R&D use. Across the pharmaceutical industry, five key data domains have been identified:
- externally-sourced molecular life science data,
- internally-generated clinical trial data with patient-centric genetic and molecular profile data;
- Real World Evidence data, including EHR and insurance claim data;
- Business intelligence data (to support R&D portfolio and in-licensing decisions);
- Telemedicine and the potential future impact of data from remote monitoring of patients on pharmaceutical delivery and R&D.
In some biomarker discovery studies over 6TB of data is already being generated per patient. Such a volume of data creates significant challenges in data security & protection, storage, sharing, integration, analysis and visualization, not to mention challenges for existing physical compute capabilities and networks. Given much of the data in question is external to any individual pharma company, new business models will need to be established involving collaboration between a multiplicity of entities including academia, CROs, government agencies, health providers, technology companies and even between the Pharmaceutical companies themselves. Only through innovative, cross-organisational cooperation will the sector be able to derive the necessary insights to translate the ‘big data’ opportunity into new medicines and improved patient health and treatment outcomes.
- Hewlett-Packard Company
- Thomson Reuters